TPMT and acute lymphoblastic leukemia: Patients with inherited poor or absent TPMT (thiopurine S-methyltransferase) activity are at increased risk for severe toxicity due to mercaptopurine, thioguanine, and azathioprine at conventional doses, and there is a recommendation for TPMT genotyping to adjust the dose for the treatment of ALL.(22)